Dr Penny Asbell joins Advisory Board at Wize Pharma
Wize Pharma, Inc., an Israel based clinical-stage biopharmaceutical company, focused on the treatment of ophthalmic disorders, recently announced that Dr Penny Asbell, a leading key opinion leader in the treatment of dry eye syndrome has joined the Company’s Advisory Board. As a principal investigator in countless clinical studies sponsored by the National Institute of Health’s National Eye Institute and by industry sponsors, Dr Asbell has participated in the development of pharmaceuticals that have included pivotal treatments for ocular conditions including dry eyes.
Dr Asbell is a professor of ophthalmology at the Icahn School of Medicine at Mount Sinai in New York City and is the director of the Cornea Service and Cornea Clinical and Research Fellowships at the Mount Sinai Hospital. She established Mount Sinai’s Lowenstein Foundation Sjogren’s Center to provide multi-specialty care for patients with dry eyes and associated systemic problems.
Dr Asbell has authored and co-authored hundreds of articles, authored 25 book chapters, and has presented over 200 lectures and courses. She has served on the board of directors of the Tear Film and Ocular Surface Society, the Cornea Society, the Eye Bank for Sight Restoration and Program Committee-Cornea for ARVO. She is currently the Deputy Editor of Eyewiki which is sponsored by the American Academy of Ophthalmology, Editor in Chief of ECL, the official journal of CLAO, and Section Editor of Cornea for BMC.